Spike Protein News and Research

RSS

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

A recent study conducted by researchers from the US aimed to measure the impact of severity of COVID-19 on memory B cell response and characterize changes in the memory B cell compartment during the period between recovery and five months after symptom onset. This study is available on the bioRxiv* preprint server.

30 Sep 2021

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

A team of scientists from the USA and France has recently unveiled the mechanism of immune dysregulation in coronavirus disease 2019 (COVID-19) patients by analyzing the early-stage interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected epithelial cells and immune cells. The study is currently available on the bioRxiv* preprint server.

30 Sep 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

30 Sep 2021

Novel framework can predict changes that may increase the infectiousness of SARS-CoV-2

As SARS-CoV-2 continues to evolve, new variants are expected to arise that may have an increased ability to infect their hosts and evade the hosts' immune systems.

29 Sep 2021

Immunocompromised patients show decreased response to SARS-CoV-2 mRNA vaccines

Researchers explore the germinal cell responses in both healthy individuals and kidney transplant patients in their recent study.

29 Sep 2021

Study finds strong evidence of transplacental passage of IgG antibodies following COVID vaccination

In the current study, researchers investigate the transplacental transmission of antibodies in vaccinated pregnant women.

29 Sep 2021

Large-scale SARS-CoV-2 spike protein mutants analysis identifies subclonal variants indicative of within-host viral diversity

Researchers have investigated a vast SARS-CoV-2 assembly and NGS data set to detect non-synonymous S protein mutations.

29 Sep 2021

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

A new preprint describes the causal role of waning antibody titers in decreased antibody persistence at one year.

29 Sep 2021

Could vitamin A help to regain your smell loss after COVID-19?

Could vitamin A help to regain your smell after COVID-19? New research is trying to find out, and we spoke exclusively to Professor Carl Philpott to find out more.

29 Sep 2021

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

The authors from this paper performed a systematic review and meta-analysis evaluating vaccine effectiveness from RCTs and observational studies.

29 Sep 2021

Human coronavirus replicates in bats without using the spike protein

Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors.

28 Sep 2021

Southeast Asia - A hotspot of many viruses with potential to cause pandemics

A new study reveals that scientists have found three viruses in bats in Laos that exhibit similar characteristic features as SARS-CoV-2.

28 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Spike Protein News and Research

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

The applications of nanomaterials against viral disease

SARS-CoV-2 infection aided by antibody-dependent enhancement

Novel framework can predict changes that may increase the infectiousness of SARS-CoV-2

Immunocompromised patients show decreased response to SARS-CoV-2 mRNA vaccines

Study finds strong evidence of transplacental passage of IgG antibodies following COVID vaccination

Large-scale SARS-CoV-2 spike protein mutants analysis identifies subclonal variants indicative of within-host viral diversity

Vaccine-induced SARS-CoV2 immune responses decline at similar rates as those after infection, study finds

Could vitamin A help to regain your smell loss after COVID-19?

How effective are COVID-19 vaccines against SARS-CoV-2 variants of concern?

Human coronavirus replicates in bats without using the spike protein

Southeast Asia - A hotspot of many viruses with potential to cause pandemics

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Researchers discover protein previously unknown to be involved in SARS-CoV-2 infection

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News